Phagocytex is a biotechnology company redefining the future of immuno-oncology through its proprietary peptide-linked CAR-Macrophage (pCAR-M) platform. Our technology enables the engineering of macrophages for personalized solid tumor therapy, covering up to 92% of all cancers in just two hours.

By overcoming the solid tumor infiltration barrier that limits CAR-T therapies, Phagocytex unlocks a massive and previously unreachable patient population. Our patented peptide linker system delivers a scalable, target-agnostic cell therapy solution that dramatically reduces manufacturing costs and accelerates development timelines.

We provide biopharma partners with a next-generation therapeutic platform that solves key economic and clinical constraints in cell therapy, opening new global market opportunities and driving the next wave of growth in precision cancer treatment.

Founder(s) Name(s)

• Prof. Lee Kin Wah Terence (Professor, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University)
• Prof. Wong Tsun Ting Clarence (Assistant Professor, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University)
• Dr. Lei Mang Leng Martina (Postdoc, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University)
• Ms. Leung Wing Hei Rainbow (PhD, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University)
  
  

Achievement(s)

• Awarded Team in PolyU-MicroFund 2025-26 Cohort 1

Patent(s)

• US provisional patent filed in 2025 (Application no. 63/929,922)

Funding Support

• PolyU-MicroFund (2025)
• HKSTP-Ideation (2025)
• RIF (R5008-22)